Takeda’s current bid implies an equivalent value of around £49 per Shire ordinary share, comprised of around £27.26 in new Takeda shares and £21.75 in cash (Press release, Shire, APR 25, 2018, View Source,_takeda_move_closer_to_merger_deal_1233173 [SID1234525666]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

At completion, Shire shareholders would own around 50 percent of the new group, with shares listed in Japan and in the US through an ADR programme.

Shire noted that the making of any firm offer by Takeda would be subject to agreement of certain other terms of the latest proposal, completion of a due diligence review by Takeda, the unanimous recommendation of the Board of Shire, and final approval by the Japanese drugmaker.